Risks of Nasal Corticosteroids in Children Under 2
Growth suppression is the primary documented risk when intranasal corticosteroids are used in toddlers under age 2, particularly with beclomethasone dipropionate at doses exceeding recommendations. 1
Key Safety Concerns in This Age Group
Growth Effects
The most clinically significant risk in toddlers is transient growth suppression, which has been specifically documented with:
- Beclomethasone dipropionate when administered to toddlers, even at recommended doses 1
- Long-term use of beclomethasone at doses exceeding recommendations 1
In contrast, fluticasone propionate, mometasone furoate, and budesonide have shown no effect on growth at recommended doses in older children 1. However, these studies were not conducted specifically in the under-2 population.
Limited FDA Approval and Safety Data
Only triamcinolone acetonide is FDA-approved down to age 2 years 2. This means:
- Most intranasal corticosteroids lack safety and efficacy data in children under 2
- The under-2 age group has not been adequately studied for most formulations
- Recommendations are largely extrapolated from older children
Systemic Absorption Risks
While studies in older children show minimal HPA axis suppression at recommended doses 1, toddlers may be at higher risk for systemic effects due to:
- Higher surface area-to-body weight ratio
- Potential for increased systemic absorption
- Recent case reports documenting systemic adverse events with locally administered corticosteroids in pediatric patients 3
Local Side Effects
Local adverse effects remain possible but rare:
- Nasal irritation and epistaxis (bleeding)
- Nasal septal perforation with prolonged use (extremely rare) 1
- These can be minimized with proper administration technique (directing spray away from septum)
Clinical Context and Alternatives
The evidence strongly suggests that intranasal corticosteroids should generally be avoided in children under 2 years unless there is a compelling clinical indication, given:
- Limited safety data in this specific age group
- Documented growth suppression risk in toddlers with certain formulations
- Lack of FDA approval for most products in this age range
- Availability of safer alternatives (second-generation oral antihistamines have excellent safety profiles in young children) 1
Monitoring Recommendations
If intranasal corticosteroids must be used in a child under 2:
- Choose formulations with better safety profiles (avoid beclomethasone dipropionate)
- Use the lowest effective dose
- Monitor growth parameters closely (height measurements at regular intervals)
- Periodically examine the nasal septum for mucosal erosions
- Consider a therapeutic trial of 4-6 weeks; discontinue if no clear benefit 4
The risk-benefit ratio generally does not favor routine use of intranasal corticosteroids in children under 2 years of age.